Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GT160-246 · 1 trial · 5 indications
| Name | Type | Description |
|---|---|---|
| GT160-246 | DRUG | - |
Inclusion Criteria: * Be at least 18 years old. * Have active mild to moderate C. difficile- Associated Diarrhea (CDAD). * Be able to tolerate oral medication. * Not be pregnant or breast-feeding. * Sign and date an informed consent form.
GT160-246 is an investigational small molecule being developed for the treatment of Clostridium difficile-associated diarrhea, a condition also known as Clostridium difficile infection. It is being studied in patients with this infectious disease, which can cause diarrhea and colitis, particularly after antibiotic use.
GT160-246 is a small molecule being developed by Sanofi for Clostridium difficile-associated diarrhea. The specific molecular target of GT160-246 has not been disclosed in the available information, so its exact mechanism of action is not detailed here.
GT160-246 is being developed by Sanofi, a global biopharmaceutical company listed on the stock exchange under the ticker symbol SNY. Sanofi is conducting clinical research on this investigational drug for the treatment of Clostridium difficile-associated diarrhea.
GT160-246 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied for safety and efficacy in patients with Clostridium difficile-associated diarrhea.
GT160-246 has been studied in one completed Phase 2 clinical trial with the identifier NCT00034294. This randomized, double-blind trial enrolled 300 patients and compared GT160-246 to vancomycin in patients with Clostridium difficile-associated diarrhea. The trial was conducted in the United States, Canada, Puerto Rico, and the United Kingdom.
No, GT160-246 is not the same as vancomycin. GT160-246 is an investigational small molecule being developed by Sanofi, while vancomycin is an established antibiotic used as a comparator in the clinical trial. The Phase 2 study evaluated GT160-246 against vancomycin in patients with Clostridium difficile-associated diarrhea.